Company profile: Odyssey Therapeutics
1.1 - Company Overview
Company description
- Provider of precision immunomodulators for inflammatory diseases and oncology medicines for cancer, enabled by a drug hunting engine combining machine learning, target biology, and medicinal chemistry. Offers target biology and discovery with CRISPR-based screening and advanced cell culture, proprietary small-molecule libraries, and predictive/data sciences.
Products and services
- Oncology Medicines: Develops precision-engineered oncology medicines to treat various forms of cancer, constructing drugs informed by target biology and medicinal chemistry
- Precision Immunomodulators: Creates clinical-grade precision immunomodulator medicines that modulate the immune system to treat inflammatory diseases, architecting therapies guided by target biology
- Drug Hunting Engine: Builds an AI-enabled platform combining machine learning, target biology, and medicinal chemistry to accelerate drug discovery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Odyssey Therapeutics
Wugen
HQ: United States
Website
- Description: Provider of off-the-shelf allogeneic cellular therapies for solid tumors and hematologic malignancies, including WU-NK-101, a memory NK cell therapy, and WU-CART-007, a CD7-targeting CAR-T for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; plus Memory NK and CAR-T platforms enabling feeder-free cryopreserved NK cells and donor-derived CAR-T cells engineered to reduce fratricide and Graft vs. Host Disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wugen company profile →
Cellerant Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage cell- and antibody-based immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellerant Therapeutics company profile →
Antigen Express
HQ: United States
Website
- Description: Provider of proprietary vaccine formulation platform and products addressing large unmet medical needs by focusing on stimulation of critical T helper cells. The technology enables antigen-specific stimulation or suppression of T-helper responses to virtually any antigen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antigen Express company profile →
Fate Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived cellular therapeutics and platform technologies, offering a proprietary clonal master iPSC platform for off-the-shelf therapies; CAR T and CAR NK candidates including FT819 (CD19 for systemic lupus erythematosus and other autoimmune diseases), FT522 (CAR NK with alloimmune defense receptor for B-cell lymphoma and autoimmune diseases), FT825 (HER2 solid tumors), plus NK and T-cell programs for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fate Therapeutics company profile →
Immunicum
HQ: Sweden
Website
- Description: Provider of clinical phase II cancer immunotherapies, including therapeutic cancer vaccines and T-cell expansion methods rooted in transplantation immunology. Offerings include Vididencel, a maintenance therapy for measurable residual disease in AML and ovarian cancer; Ilixadencel, an intratumoral immune primer of pro-inflammatory donor dendritic cells for combination treatment of hard-to-treat solid tumors; and a preclinical memory NK-cell expansion platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunicum company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Odyssey Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Odyssey Therapeutics
2.2 - Growth funds investing in similar companies to Odyssey Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Odyssey Therapeutics
4.2 - Public trading comparable groups for Odyssey Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →